Inflammatory macrophage derived TNFα downregulates estrogen receptor α via FOXO3a inactivation in human breast cancer cells.


Journal

Experimental cell research
ISSN: 1090-2422
Titre abrégé: Exp Cell Res
Pays: United States
ID NLM: 0373226

Informations de publication

Date de publication:
01 05 2020
Historique:
received: 04 12 2019
revised: 24 02 2020
accepted: 27 02 2020
pubmed: 8 3 2020
medline: 15 12 2020
entrez: 8 3 2020
Statut: ppublish

Résumé

Patients with estrogen receptor α positive (ERα

Identifiants

pubmed: 32145253
pii: S0014-4827(20)30137-3
doi: 10.1016/j.yexcr.2020.111932
pii:
doi:

Substances chimiques

Estrogen Receptor alpha 0
FOXO3 protein, human 0
Forkhead Box Protein O3 0
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

111932

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest KL is a board member of Cantargia AB, a company developing IL1RAP inhibitors. This does not alter the Author's adherence to all guidelines for publication. The authors otherwise declare no competing interest.

Auteurs

Frida Björk Gunnarsdóttir (FB)

Cancer Immunology, Department of Translational Medicine, 214 28, Malmö, Lund University, Sweden.

Catharina Hagerling (C)

Cancer Immunology, Department of Translational Medicine, 214 28, Malmö, Lund University, Sweden; Division of Clinical Genetics, Department of Laboratory Medicine Lund, Lund University, 221 00, Lund, Sweden.

Caroline Bergenfelz (C)

Cancer Immunology, Department of Translational Medicine, 214 28, Malmö, Lund University, Sweden.

Meliha Mehmeti (M)

Cancer Immunology, Department of Translational Medicine, 214 28, Malmö, Lund University, Sweden.

Eva Källberg (E)

Cancer Immunology, Department of Translational Medicine, 214 28, Malmö, Lund University, Sweden.

Roni Allaoui (R)

Cancer Immunology, Department of Translational Medicine, 214 28, Malmö, Lund University, Sweden.

Sofie Mohlin (S)

Division of Pediatrics, Department of Clinical Sciences Lund, Lund University, 221 00, Lund, Sweden.

Sven Påhlman (S)

Translational Cancer Research, TCR, Medicon Village, Lund University, 221 00, Lund, Sweden.

Christer Larsson (C)

Translational Cancer Research, TCR, Medicon Village, Lund University, 221 00, Lund, Sweden.

Karin Jirström (K)

Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, 221 00, Lund, Sweden.

Daniel Bexell (D)

Translational Cancer Research, TCR, Medicon Village, Lund University, 221 00, Lund, Sweden.

Karin Leandersson (K)

Cancer Immunology, Department of Translational Medicine, 214 28, Malmö, Lund University, Sweden. Electronic address: Karin.Leandersson@med.lu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH